These changes in weight and body composition increase the risk for cardiometabolic diseases, as evidenced by the increased prevalence of type 2 diabetes, dyslipidemia, metabolic dysfunction-associated steatotic liver disease (MASLD-previously referred to as nonalcoholic fatty liver disease), and cardiovascular disease (CVD) after menopause
[114] randomized subjects to semaglutide or placebo to observe the change of liver fat from baseline to week 48, and found that semaglutide significantly reduced hepatic steatosis, improved liver enzymes and metabolic parameters, and had a positive effect on the diagnosis and treatment of NAFLD compared with placebo
This does not imply universal conclusions, but it emphasises the importance of professional judgement in risk profiles or in people with pathologies
Take Glutathione+l Arginine+proanthocyanidin as advised by your doctor
Delivered as a pre-filled injection pen at standardized dosages